Healthcare

Neurodegenerative Disorder Therapeutics Market   accounted for US$ 9.32 billion in 2019 and is estimated to be US$ 21.3 billion by 2029 and is anticipated to register a CAGR of 8.7% The report " Global  Neurodegenerative Disorder Therapeutics Market, By  Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, and Other Indication Types), By Drug Type (N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, and Other Drug Types), By Distribution (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy),  and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029” . Key Highlights: In November 2019, Alkermes plc and Rodin Therapeutics, Inc. announced that they have entered into a definitive agreement under which Alkermes will acquire Rodin, a privately held biopharmaceutical company focused on developing novel,

  Bovine Lactoferrin Market   accounted for US$ 572.6 Million in 2020 and is estimated to be US$ 912.3 Million by 2029 and is anticipated to register a CAGR of 5.3%. The report " Global Bovine Lactoferrin Market,  By Product ( Spray-dried, and Freeze-dried ), By Application ( Infant Formula, Pharmaceuticals, Dietary Supplements, Food, and Others ),   and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029” . Key Highlights: In April 2018, Ingredia announced the launch of a new product in the lactoferrin space. The company introduced PROFERRIN lactoferrin in the global market. This product was intended to be used in improving gut health and to exhibit anti-microbial and anti-inflammatory properties . In March 2019, Hong Kong Jin Gang Trade Holding Limited announced that it has completed the acquisition of Westland Co-operative Dairy Company Limited with an aim to strengthen its market position in

A small clinical trial discovered that every single rectal cancer patient who got an experimental treatment saw their disease vanish, in what looks to be a miracle and a "first in history". According to the New York Times, 18 patients took a medicine named Dostarlimab for six months in a limited clinical trial done by Memorial Sloan Kettering Cancer Center, and all of them saw their tumours shrink at the end. Experts stated that the malignancy is undetectable by physical examination, endoscopy, positron emission tomography or PET scans, or MRI scans. This shows that Dostarlimab has the potential to be a 'possible' cancer cure for one of the most lethal tumours. For Further Info:- https://bit.ly/3mpHiT4